Gross profit for the year fell by some 13% y-o-y to RMB2.52 billion. Gross profit margin fell three percentage points to 38% in the same period.
Tianjin Zhong Xin Pharmaceutical Group Corporation has recorded earnings of RMB661.7 million ($135.8 million) or 0.86 RMB cents per share for the FY2020 ended December, 6% higher than earnings of RMB625.6 million a year ago.
FY2020 revenue fell 6% y-o-y to RMB6.60 billion largely due to lower revenue brought in by the group’s Chinese medicine segment.
